For example, a clinical trial of pembrolizumab and another trial of durvalumab in patients with HIV on anti-retroviral therapy and advanced-stage cancer, reported that both therapies did not impair CD4 + cell counts or viral suppression [21, 22]. The gene discussed is CD4; the disease is cancer.